Expertise in
11
conditions

Volkmar C. Muller

Hamburg, HH, DE 
Expertise in
11
conditions
Hamburg, HH, DE 

Overview

Volkmar Muller practices practicing medicine in Hamburg, Germany.

Muller is highly rated in 11 conditions, according to our data. Their clinical expertise encompasses Breast Cancer, HER2 Negative Breast Cancer, Triple-Negative Breast Cancer, Hepato-Pancreato-Biliary Surgery, and Mastectomy.

They are actively involved in clinical research, co-authoring 489 peer reviewed articles and participating in 3 clinical trials.

Locations

Hamburg, HH, Germany
Other Locations
Eppendorf, HH, Germany
Hannover, NI, Germany
Frankfurt Am Main, HE, Germany
Mannheim, BW, Germany
Regensburg, BY, Germany
Moenchengladbach, NW, Germany
Rostock, MV, Germany
Head And Neck Surgery, Koeln, NW, Germany
Dortmund, NW, Germany
Marburg An Der Lahn, HE, Germany
Berlin, BE, Germany
Muenster, NW, Germany
Pinneberg, SH 25421, Germany
Erlangen, BY, Germany
Offenbach, HE, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2026
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
An Exploratory Safety and Immunogenicity Study of Human Papillomavirus (HPV16+) Immunotherapy VB10.16 in Women With High Grade Cervical Intraepithelial Neoplasia (HSIL; CIN 2/3)
An Exploratory Safety and Immunogenicity Study of Human Papillomavirus (HPV16+) Immunotherapy VB10.16 in Women With High Grade Cervical Intraepithelial Neoplasia (HSIL; CIN 2/3)
Enrollment Status: Completed
Publish Date: July 13, 2022
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

489 Total Publications

Clinical Relevance of Post-Treatment Circulating Tumor DNA Detection in Early Breast Cancer Using a Tissue-Free Epigenomic Assay: A 2-Year Landmark Analysis.
Clinical Relevance of Post-Treatment Circulating Tumor DNA Detection in Early Breast Cancer Using a Tissue-Free Epigenomic Assay: A 2-Year Landmark Analysis.
Journal: JCO precision oncology
Published: September 04, 2026

Frequently Asked Questions about Volkmar C. Muller

Is Volkmar C. Muller a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Volkmar C. Muller is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Volkmar C. Muller participate in research or clinical trials?

Yes. Volkmar C. Muller has published 489 articles and abstracts on conditions like Breast Cancer. You can view a list of Volkmar C. Muller's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Muller's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile